SciBase Concludes Warrant Repurchase Offer
SciBase Holding AB (publ) has successfully announced the results of its recent warrant repurchase initiative, designed for holders of series TO 2 warrants. This significant development, completed pursuant to the Board’s decision, opens a new chapter for the company's commitment to enhancing shareholder value.
Details of the Repurchase Offer
In total, an astonishing number of 418,150,952 warrants of series TO 2 were accepted, effectively translating to a substantial 83.9 percent acceptance rate. Each two warrants of this series allowed for the purchase of one share in SciBase, culminating in the creation of 209,075,476 new shares—an impressive infusion into the company’s capital structure.
This repurchase offer ran its course from December 8 to January 8. Prior to this, SciBase had successfully gathered commitments from a consortium of investors to surrender 368,709,753 warrants, making up approximately 74 percent of total outstanding series TO 2 warrants. The high acceptance rate not only illustrates shareholders' confidence but also reflects positively on SciBase's strategic positioning.
Impact on Company Shares
The completion of the TO 2 Offer is set to cause a dilution of approximately 33.5 percent among existing shares, calculating from the total number of shares post-offer. Following this event, the remaining outstanding warrants of this series will total 80,383,883, paving a way for future opportunities within the marketplace.
According to the Board of Directors, the subscription for the new shares will occur through a directed set-off issue, specifically arranged for those who have participated in the offer. This Set-off Issue is tentatively scheduled for January 27, showcasing the company’s efficiency in processing shareholder transactions.
Share Capital Increase
The TO 2 Offer significantly boosts SciBase’s share capital by SEK 10,453,773.80 through the newly issued shares. This increase not only reflects the ongoing growth of the company but also enhances its stability and market position.
Strategic Advisors to the Initiative
In facilitating these changes, SciBase has engaged with various advisors. Financial experts from Bergs Securities and Birchtree Advisory have provided crucial insights, while Advokatfirman Schjødt has ensured legal compliance during this process. Their collective expertise plays a vital role in supporting profitable outcomes for shareholders.
Contact Information
Should investors or interested parties have any questions regarding these developments, they may reach out to Jesper Høiland, Chairman of the Board, or Michael Colérus, CFO, through the provided phone details. This direct line of communication encourages transparency and fosters a sense of community within the SciBase family.
About SciBase
SciBase stands as a beacon of innovation within the medical technology sector, emphasizing early detection and prevention strategies in dermatology. Through the flagship product, Nevisense, the company has integrated AI with advanced electrical impedance spectroscopy (EIS) that enhances diagnostic accuracy. SciBase’s dedication lies in alleviating patient suffering, supporting medical professionals in their quest to save lives while also minimizing healthcare costs.
With a foundation of over 20 years of research initiated at the Karolinska Institutet, SciBase has positioned itself as a leader in dermatological advancements. The commitment to innovation solidifies their status as a publicly listed entity on the Nasdaq First North Growth Market since June 2, 2015, highlighting their growth trajectory.
Frequently Asked Questions
What is the main purpose of the TO 2 Offer?
The TO 2 Offer facilitates the repurchase of outstanding warrants, allowing shareholders to convert them into newly issued shares of SciBase.
How many warrants were repurchased through the TO 2 Offer?
A total of 418,150,952 series TO 2 warrants were accepted, translating to an 83.9 percent acceptance rate.
What will be the impact on share capital following the offer?
The company’s share capital will increase by SEK 10,453,773.80 with the issuance of new shares resulting from the TO 2 Offer.
Who were the advisors involved in this initiative?
SciBase engaged Bergs Securities and Birchtree Advisory as financial advisors, along with legal counsel from Advokatfirman Schjødt.
How can I learn more about SciBase and its operations?
For additional information, you can reach out to the company directly or visit their official website for comprehensive resources and support.
